Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
US12357586B2 · kind B2 · utility
0Cited by
76References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 26, 2022 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Jan 26, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.